Acurx Pharmaceuticals Stock Is Plummeting After Biotech Publishes Phase 2 Results
Portfolio Pulse from Vandana Singh
Acurx Pharmaceuticals Inc's stock is trading lower after the company published efficacy results from a Phase 2 trial. The company had decided to terminate the Phase 2b vancomycin-controlled trial segment early due to high observed clinical cure rate and no emerging safety concerns. The clinical cure rate for ibezapolstat, to treat C. difficile Infection (CDI), was projected to be at least 90%. Other factors, including the cost and the challenging enrollment due to the COVID-19 pandemic, also influenced the decision. The stock is down more than 31%.
November 02, 2023 | 4:12 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Acurx Pharmaceuticals' stock is trading lower after the company published efficacy results from a Phase 2 trial. The company had decided to terminate the Phase 2b trial early due to high clinical cure rate and no safety concerns. The stock is down more than 31%.
The stock price of Acurx Pharmaceuticals has dropped significantly after the company published the results of its Phase 2 trial. The decision to terminate the Phase 2b trial early due to high clinical cure rate and no safety concerns has likely contributed to the drop in the stock price. The challenging enrollment due to the COVID-19 pandemic and the cost of the trial may have also influenced the decision and the subsequent drop in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100